Gambro BCT announces red blood cell Pathogen Eradication Technology (PET) performance
Gambro BCT announces red blood cell Pathogen Eradication Technology (PET) performance Stockholm, Sweden, November 3, 2000 - Gambro AB (OM Stockholm Exchange: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, today announced its red blood cell performance achievements with PET. Gambro BCT has previously released information on the use of Riboflavin (vitamin B(2)) to inactivate viruses and bacteria in platelets and plasma. Dr. Ray Goodrich and Dr. Mike McAteer, Therapy Scientists for Gambro BCT, will both be presenting information on PET red blood cell